Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Avilar Therapeutics

Request full access

Pioneering the discovery and development of extracellular protein degraders

Watertown, United StatesFounded 2020Biotech & Life Sciences

About Avilar Therapeutics

Avilar Therapeutics is a biotech startup that is pioneering a new approach to drug development by focusing on the degradation of extracellular proteins. The company operates in the pharmaceutical industry, specifically in the area of drug discovery and development.

Traditionally, drug development has focused on intracellular targets, but Avilar is extending this to include extracellular and membrane-bound proteins. This is significant because nearly 40% of human proteins are located outside the cell and many of these play a key role in the development of human diseases. By developing drugs that can degrade these proteins, Avilar aims to create new treatments for a range of serious diseases.

Avilar's business model revolves around the development of a new class of drugs known as ATACs (ASGPR Targeting Chimeras). These are designed to harness the body's natural process for protein degradation. The company has developed a unique, integrated, and modular drug discovery platform that allows for the design and assembly of ATACs targeting a wide array of extracellular proteins.

The company's revenue model is likely to be based on the successful development and commercialization of these new drugs, either through direct sales or through partnerships with larger pharmaceutical companies.

In summary, Avilar is a cutting-edge biotech company that is pushing the boundaries of drug development by targeting extracellular proteins. Its innovative approach could potentially lead to the development of new treatments for a range of serious diseases.

Source: Dealroom company data

At a glance

Status
Operational
Employees
24
Open positions
None listed
Dealroom signal
63.4/100
Industry
Health
Sub-industry
BioTechnology
Sector
Biotechnology, Biotech and Pharma, Hard Tech, proteomics, DT and LS, science-based
Business model
Manufacturing
Client focus
B2B

Funding history

2 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SEEDOther financing Feb 2023 $15M $300M RA Capital Management · Astellas Venture · Sanofi Ventures · Medical Excellence Capital ↗
SEEDOther financing Nov 2021 $60M $240M RA Capital Management ↗
Showing the latest 2 of 2 recorded eventsBook a demo for the full funding history →

Growth signals

Avilar Therapeutics website traffic

Latest recorded traffic for Avilar Therapeutics is 3.1K monthly website visits, up 93.8% over the last three months. Avilar Therapeutics's team declined 4% over the past year.

Latest monthly visits3.1K 3-month web change+93.8% 1-year team growth-4%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Avilar Therapeutics in the Watertown ecosystem

Live from Dealroom

The Avilar Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

4 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Seed4 investors entered at this stage

Team profiled 3 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 3 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
1 countries with
team presence
🇺🇸 United States100%
1 country shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Avilar Therapeutics on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Avilar Therapeutics’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.